Respiratory Market Insight 2008

Table of Contents

Chapter 1 Executive Summary

• 1.1 The Respiratory Treatment Market Has High Potential
• 1.2 Combination Class Leads the Market
• 1.3 GSK Dominates the Market
• 1.4 Aims, Scope and Format of the Report

Chapter 2 Introduction

• 2.1 Respiratory Diseases Overview
• 2.2 What is Asthma?
  • 2.2.1 Causes of Asthma
  • 2.2.2 Asthma Triggers
  • 2.2.3 Asthma Rates Have Exploded in Recent Years
  • 2.2.4 The Economic Cost of Asthma Has Increased
  • 2.2.5 Asthma: Drug Treatments
  • 2.2.6 Inhaler is Main Delivery Method for Asthma
• 2.3 Chronic Obstructive Pulmonary Disease (COPD)
  • 2.3.1 Chronic Bronchitis
  • 2.3.2 Emphysema
  • 2.3.3 Symptoms of COPD
  • 2.3.4 Management of COPD
  • 2.3.5 Frequent Exacerbations in Patients with COPD
• 2.4 Upper Respiratory Infections (URI)
  • 2.4.1 Common Cold
  • 2.4.2 Influenza
  • 2.4.3 Sinusitis
  • 2.4.4 Pharyngitis / Tonsillitis
  • 2.4.5 Allergic Rhinitis
• 2.5 Major Drug Classes in Treating Respiratory Diseases
  • 2.5.1 Combination
  • 2.5.2 Leukotriene Inhibitors
  • 2.5.3 Corticosteroids
  • 2.5.4 Beta-2 (Adrenoreceptor) Agonists
  • 2.5.5 Antihistamines
  • 2.5.6 Monoclonal Antibodies
  • 2.5.7 Summary of Major Products in the Respiratory Market

Chapter 3 The Global Respiratory Disease Drug Market

• 3.1 The Global Respiratory Disease Drug Market Will Grow During 2008-2013
• 3.2 GSK Currently Leads the Respiratory Market
• 3.3 Combination Drugs to Continue Their Domination of the Respiratory Disease Market, 2006 Onwards
• 3.4 Other Classes of Respiratory Drugs Will Display High Revenues during 2006-2013
• 3.5 Antihistamines - Declining Revenues due to Heightened Competition
• 3.6 B2-Stimulants - Will This Class Be Superseded by the Combination Drugs?
• 3.7 Corticosteroids - Carving a Secure Niche in a Highly Competitive Market
• 3.8 Leukotriene Inhibitors Will Maintain a Respected Position in the Respiratory Market
• 3.9 Competition in the Respiratory Disease Drug Market to Become Increasingly Intense

Chapter 4 The World Market for Combination Drugs, 2008-2013

• 4.1 Combination Drugs - Strong Growth Leads to Continuing Predominance in the Market
  • 4.1.1 Will the Combination Drugs Hold Their Dominance Towards the End of the Forecast Period?
• 4.2 GSK' s Advair/Seretide Currently Leads the Respiratory Market
  • 4.2.1 Advair/Seretide Benefits From High Prescription Rates in the US Market
  • 4.2.2 Advair/Seretide Benefits from Further Clinical Studies
• 4.3 Symbicort - High Revenues Followed by Decline
  • 4.3.1 New Formulation and Delivery Method Looks Promising
  • 4.3.2 New Dosing Regime May Offer Symbicort Significant Market Advantages
  • 4.3.3 Is AstraZeneca Pushing Towards a New Model of Asthma Treatment?
• 4.4 Combivent Will Reach Blockbuster Status

Chapter 5 The World Market for Antihistamines, 2008-2013

• 5.1 Increased Competition Will Lower Revenues Among the Antihistamines
• 5.2 Will Pfizer' s Zyrtec Still Dominate the Antihistamine Market After Patent Expiration?
  • 5.2.1 Zyrtec Faces Generic Competition
• 5.3 Allegra/Telfast Will Decline in Revenue
  • 5.3.1 Allegra/Telfast has Some Positive and Negative Clinical Data
• 5.4 Clarinex/Aerius Will Show Some Positive Growth but then Gradually Decline

Chapter 6 The World Market for Corticosteroids, 2008-2013

• 6.1 Corticosteroids Will Retain Their Niche Despite a Marked Decline in Sales
• 6.2 Pulmicort from AstraZeneca is the Market Leader - But will it Last?
  • 6.2.1 Why Will Pulmicort' s Revenue Drop?
• 6.3 Flovent/Flixotide Will Gradually Decline in Sales
• 6.4 Nasonex Will Become the Leading Product in this Market
  • 6.4.1 Nasonex Benefits From the Patent Expiry of Other Leading Products in this Class
• 6.5 Summary - Corticosteroids

Chapter 7 The World Market for Leukotriene Inhibitors, 2008-2013

• 7.1 Singulair Dominates the Leukotriene Inhibitor Class
• 7.2 Summary - Leukotriene Inhibitors

Chapter 8 The World Market for Monoclonal Antibodies, 2008-2013

• 8.1 The Monoclonal Antibodies Will Face Decreased Growth
• 8.2 MedImmune' s Synagis Leads This Market
  • 8.2.1 Synagis Benefits from Further Clinical Studies
• 8.3 Xolair Shows Steady Growth - Will it Become the New Market Leader?

Chapter 9 The World Market for B2-Stimulants, 2008-2013

• 9.1 B2-Stimulants Will Lose Prominence in the Respiratory Market
• 9.2 Xopenex Will Dominate the B2-Stimulants Class Despite Mixed Growth
• 9.3 Serevent Loses Revenue Despite Patent Protection
• 9.4 Recent Study Confirms Increased Risk With Beta-2 Agonist Usage
• 9.5 Summary - Beta-2 Agonists

Chapter 10 Analysis of Factors That Influence the Respiratory Market

• 10.1 SWOT Analysis of the Respiratory Market
• 10.2 An Expanding Patient Population Constitutes the Principal Driver in the Respiratory Market
  • 10.2.1 The Respiratory Disease Market Has High Potential and Opportunities
  • 10.2.2 Growth in this Market Is Driven by Epidemiological Factors
  • 10.2.3 Lifecycle Management Strategies Will Become More Prominent to Protect Soon-to-be Off-patent Drugs
  • 10.2.4 Brand Awareness in the Respiratory Disease Market
• 10.3 The Principal Restraints in the Respiratory Market
  • 10.3.1 To What Extent is the Respiratory Market Threatened by Generic Substitutes?
  • 10.3.2 Warnings Act as Restraints to Market Growth
  • 10.3.3 Comparative Studies - A Two Edged Sword
• 10.4 What has Caused a Broadening of the Focus in Respiratory Drug Development?
• 10.5 Respiratory Disease - A Unique Market Based on Management Rather than Cure
• 10.6 Increasing Investment in the ' Cinderella Sector'
• 10.7 The Future for Respiratory Disease Research and Development and the Increasing Focus on COPD
• 10.8 The Importance of Education in the Future of the Respiratory Disease Market
• 10.9 Is the Early Treatment of Asthma the Way Ahead?

Chapter 11 Respiratory Pipeline Products

• 11.1 Summary of All Respiratory Pipeline Products
• 11.2 The Respiratory Pipeline is Large
• 11.3 NVA237 and QVA149 for COPD
• 11.4 New Companies Seek Entrance Into a Potentially Lucrative Market
• 11.5 The Potential of the Respiratory Market Has Encouraged R&D
• 11.6 Innovation Rules For Early Stage Pipeline Drugs
• 11.7 Respiratory Pipeline Shows Short- and Long-Term Potential

Chapter 12 Conclusion

• 12.1 The Respiratory Market Constitutes a High Revenue Market with Continuing Growth Potential
• 12.2 Combination Class Will Dominate During the Forecast Period
• 12.3 Unmet Needs in the Market
• 12.4 Future Opportunities in the Respiratory Market

List of Tables

• Table 1.1 Blockbuster Drugs in the World Respiratory Market
• Table 2.1 Summary of the Major Products in the Respiratory Market and Revenues ($m), 2006
• Table 3.1 Blockbuster Drugs in the World Respiratory Disease Market, 2006
• Table 3.2 World Revenues ($m) for the Leading Respiratory Drugs, by Class, 2008-2013
• Table 3.3 World Market Revenue ($m), 7-Year CAGR (%) and Market Share (%) for Respiratory Drugs by Class, 2006 & 2013
• Table 4.1 World Revenues ($m) for Combination Drugs, 2008-2013
• Table 4.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Combination Drugs, 2006 & 2013
• Table 5.1 World Revenues ($m) for Antihistamines, 2008-2013
• Table 5.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Antihistamines, 2006 & 2013
• Table 6.1 World Revenues ($m) for Corticosteroids, 2008-2013
• Table 6.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Corticosteroids, 2006 & 2013
• Table 7.1 World Revenues ($m) and Growth Rate (%) for Singulair, 2008-2013
• Table 8.1 World Revenues ($m) for Monoclonal Antibodies, 2008-2013
• Table 8.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Monoclonal Antibodies, 2006 & 2013
• Table 9.1 World Revenues ($m) for B2-Stimulants, 2008-2013
• Table 9.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for B2-Stimulants, 2006 & 2013
• Table 10.1 A SWOT Chart for the Respiratory Market, 2008-2013
• Table 11.1 Pipeline Drugs for Respiratory Diseases, 2008

List of Figures

• Figure 1.1 Market Share (%) for the Respiratory Market by Company, 2006
• Figure 3.1 World Revenues ($m) for the Leading Respiratory Drugs, by Class, 2008-2013
• Figure 3.2 World Revenues ($m) for the Leading Respiratory Drugs, by Class, 2008-2013
• Figure 3.3 World Market Share (%) for Respiratory Drugs by Class, 2006
• Figure 3.4 World Market Share (%) for Respiratory Drugs by Class, 2013
• Figure 4.1 Total World Revenues ($m) for Combination Drugs, 2008-2013
• Figure 4.2 World Revenues ($m) for the Combination Drugs by Leading Product, 2008-2013
• Figure 4.3 World Market Share (%) for Combination Drugs by Leading Product, 2006
• Figure 4.4 World Market Share (%) for Combination Drugs by Leading Product, 2013
• Figure 4.5 World Advair/Seretide Revenues ($m), 2008-2013
• Figure 4.6 World Symbicort Revenues ($m), 2008-2013
• Figure 4.7 World Combivent Revenues ($m), 2008-2013
• Figure 5.1 Total World Revenues ($m) for Antihistamines, 2008-2013
• Figure 5.2 World Revenues ($m) for the Antihistamines by Leading Product, 2008-2013
• Figure 5.3 World Market Share (%) for Antihistamines by Product, 2006
• Figure 5.4 World Market Share (%) for Antihistamines by Product, 2013
• Figure 5.5 World Zyrtec Revenues ($m), 2008-2013
• Figure 5.6 World Allegra/Telfast Revenues ($m), 2008-2013
• Figure 5.7 World Clarinex/Aerius Revenues ($m), 2008-2013
• Figure 6.1 Total World Revenues ($m) for Corticosteroids, 2008-2013
• Figure 6.2 World Revenues ($m) for the Corticosteroids by Leading Product, 2008-2013
• Figure 6.3 World Market Share (%) for Corticosteroids, 2006
• Figure 6.4 World Market Share (%) for Corticosteroids, 2013
• Figure 6.5 World Pulmicort Revenues ($m), 2008-2013
• Figure 6.6 Flovent/Flixotide Revenues ($m), 2008-2013
• Figure 6.7 World Nasonex Revenues ($m), 2008-2013
• Figure 7.1 World Revenues ($m) for Singulair, 2008-2013
• Figure 8.1 Total World Revenues ($m) for Monoclonal Antibodies, 2008-2013
• Figure 8.2 World Revenues ($m) for the Monoclonal Antibodies by Leading Product, 2008-2013
• Figure 8.3 World Market Share (%) for Monoclonal Antibodies, 2006
• Figure 8.4 World Market Share (%) for Monoclonal Antibodies, 2013
• Figure 8.5 World Synagis Revenues ($m), 2008-2013
• Figure 8.6 World Xolair Revenues ($m), 2008-2013
• Figure 9.1 Total World Revenues ($m) for B2-Stimulants, 2008-2013
• Figure 9.2 World Revenues ($m) for the B2-Stimulants by Leading Product, 2008-2013
• Figure 9.3 World Market Share (%) for B2-Stimulants, 2006
• Figure 9.4 World Market Share (%) for B2-Stimulants, 2013
• Figure 9.5 World Xopenex Revenues ($m), 2008-2013
• Figure 9.6 World Serevent Revenues ($m), 2008-2013

List of Companies Mentioned

• 3M
• Abbott
• Actelion
• Almirall
• ALZA
• AstraZeneca
• Barrier Therapeutics
• Boehringer Ingelheim
• Chiesi
• Chugai
• Collegium
• Eli Lilly
• Evolutec
• FAES
• Forest
• Genentech
• GSK
• Inspire
• Inverseon
• Johnson & Johnson
• Kyorin
• MAP Pharmaceuticals
• Meda
• MediciNova
• MedImmune
• Menarini
• Merck
• Merck KGaA
• Mitsubishi Tanabe Pharma
• NicOx
• Nippon Shinyaku
• Novartis
• Nycomed Pharma
• Orexo
• Pfizer
• Pierre Fabre
• Purdue/Mundipharma
• Rigel
• Roche
• Rottapharm
• Sanofi-Aventis
• Schering Plough
• Scripps Research Institute
• Sepracor
• Shionogi
• Sosei
• Theravance
• Topigen
• Vectura
• Wyeth
• Yuhan